Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Brain

Volumn 132, Issue 4, 2009, Pages 1093-1101

  Paleologou, Katerina E ^a   Kragh, Christine L ^b   Mann, David M A ^c   Salem, Sultan A ^a   Al Shami, Rania ^d   Allsop, David ^a   Hassan, Ahmed H ^d   Jensen, Poul H ^b   El Agnaf, Omar M A ^d  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Amyloid oligomers; Dementia with Lewy bodies; Neurodegeneration; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; OLIGOMER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; DEMENTIA; FEMALE; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; PRIORITY JOURNAL;

EID: 65249162241     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn349     Document Type: Article

References (50)

1. Amer DA, Irvine GB, El-Agnaf OM. Inhibitors of α-synuclein oligomer-ization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 2006; 173: 223-33.
2. Braak H, Braak E. Neuropathological stageing of Alzheimer-type pathological changes. Acta Neuropathol 1991; 82: 239-59.
3. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-11.
4. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9.
5. Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000; 39: 2552-63.
6. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005; 74: 29-52.
7. El-Agnaf OMA, Jakes R, Curran MD, Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998a; 440: 67-70.
8. El-Agnaf OMA, Jakes R, Curran MD, Middleton D, Ingentto R, Bianchi E, et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett 1998b; 440: 71-5.
9. El-Agnaf OM, Irvine GB. Review: formation and properties of amyloidlike fibrils derived from α-synuclein and related proteins. J Struct Biol 2000; 130: 300-9.
10. El-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of α-synuclein and related peptides. Biochem Soc Trans 2002; 30: 559-65.
11. El-Agnaf OM, Mahil DS, Patel BP, Austen BM. Oligomerization and toxicity of p-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 2000; 273: 1003-7.
12. El-Agnaf OM, Nagala S, Patel BP, Austen BM. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 2001; 310: 157-68.
13. El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, et al. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004; 18: 1315-7.
14. El-Agnaf OMA, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003a; 17: 1945-7.
15. El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-25.
16. El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2003b; 2: 461-2.
17. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002; 34: 521-33.
18. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 1990; 9: 4225-30.
19. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-71.
20. Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, et al. Binding of Aβ to α- and β-synucleins: identification of segments in α-synuclein/NAC precursor that bind Aβ and NAC. Biochem J 1997; 323: 539-46.
21. Jensen PH, Islam K, Kenney J, Nielsen MS, Power J, Gai WP. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds α-synuclein filaments. J Biol Chem 2000; 275: 21500-7.
22. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, et al. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159: 2215-25.
23. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
24. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch MP, et al. Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies. Acta Neuropathol 2006; 111: 101-8.
25. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11: 556-61.
26. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8.
27. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
28. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-102.
29. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by α-synuclein fibrils and oligomers. J Biol Chem 2004; 279: 12924-34.
30. Lindersson E, Lundvig D, Petersen C, Madsen P, Nyengaard JR, Højrup P, et al. P25α stimulate α-synuclein aggregation and is coloca-lized with aggregated α-synuclein in α-synucleinopathies. J Biol Chem 2005; 280: 5703-15.
31. Lippa CF, Fujiwara H, Mann DM, Giasson B, Schmidt ML, Nee LE, et al. Lewy bodies contain altered α-synuclein in brains in many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998; 153: 1365-70.
32. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 2002; 99: 10813-8.
33. Martin FL, Williamson SJ, Paleologou KE, Allsop D, El-Agnaf OM. Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept Lett 2004; 3: 229-37.
34. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-9.
35. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
36. McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
37. Mirra SS, Heyman A, McKeel D. The consortium to establish a registry for Alzheimer's disease. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
38. Paleologou KE, Irvine GB, El-Agnaf OMA. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem Soc Trans 2005; 33: 1106-10.
39. Perry RK, Irving D, Blessed G, Fairburn A, Perry EK. Senile dementia of Lewy body type: a clinically and neuropathologically distinct type of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119-39.
40. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
41. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's disease and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054-61.
42. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA. The formation of highly soluble oligomers of α-synculein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37: 583-95.
43. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
44. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73.
45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
46. Tabner BJ, El-Agnaf OMA, Turnbull S, German MJ, Paleologou KE, Hayashi Y, et al. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer's disease and familial British dementia. J Biol Chem 2005b; 280: 35789-92.
47. Tabner BJ, Turnbull S, Fullwood NJ, German M, Allsop D. The production of hydrogen peroxide during early-stage protein aggregation: a common pathological mechanism in different neurodegenerative diseases? Biochem Soc Trans 2005a; 33: 548-50.
48. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid p-protein potently inhibit hip-pocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
49. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, et al. Certain inhibitors of synthetic Aβ fibrillogenesis block oligomerization of natural Aβ and thereby rescue long term potentiation. J Neurosci 2005; 25: 2455-62.
50. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73.